Identifying bioactive phytoconstituents as C-terminal Src kinase inhibitors: a virtual screening and molecular simulation approach

J Biomol Struct Dyn. 2023;41(22):13415-13424. doi: 10.1080/07391102.2023.2176362. Epub 2023 Feb 8.

Abstract

Tyrosine-protein kinase CSK otherwise known as C-terminal Src kinase (CSK), is involved in multiple pathways and processes, including regulating cell growth, differentiation, migration, and immune responses. Altered expression of CSK has been associated with various complexities, including cancer, CD45 deficiency, Osteopetrosis and lupus erythematosus. Important auxiliary roles of CSK in cancer progression make it a crucial target in developing novel anticancer therapy. Thus, CSK inhibitors are of concern as potent immuno-oncology agents. In this perspective, phytochemicals can be a significant source for unraveling novel CSK inhibitors. In this study, we carried out a systematic structure-based virtual screening of bioactive phytoconstituents against CSK to identify its potential inhibitors. After a multi-step screening process, two hits (Shinpterocarpin and Justicidin B) were selected based on their druglike properties and binding affinity towards CSK. The selected hits were further analyzed for their stability and interaction via all-atom molecular dynamics (MD) simulations. The selected hits indicated their potential as selective binding partners of CSK, which can further be used for therapeutic development against CSK-associated malignancies.Communicated by Ramaswamy H. Sarma.

Keywords: ADMET evaluation; Tyrosine-protein kinase CSK; bioactive phytoconstituents; drug discovery; molecular dynamics simulation; virtual screening.

MeSH terms

  • CSK Tyrosine-Protein Kinase / metabolism
  • Humans
  • Molecular Dynamics Simulation
  • Neoplasms*
  • src-Family Kinases* / metabolism

Substances

  • CSK Tyrosine-Protein Kinase
  • src-Family Kinases